Kim Brewer1, 2, Kerry Lake3, Nicole Pelot3, 4, Drew DeBay3, Andrea Penwell1, Genevieve Weir1, Marc Mansour1, Chris Bowen, 23
1Immunovaccine Inc., Halifax, NS, Canada; 2School of Biomedical Engineering, Dalhousie University, Halifax, NS, Canada; 3Institute for Biodiagnostics (Atlantic), National Research Council of Canada, Halifax, NS, Canada; 4Electrical Engineering, Dalhousie University, Halifax, NS, Canada
DepoVaxTM is a liposome-in-oil-based vaccine platform that uses tumor-associated antigens (TAA) encapsulated in liposomes and suspended in oil. The oil acts as an adjuvant that increases the potency of the vaccine. By attaching superparamagnetic iron oxide (SPIO) to the TAA and then encapsulating in liposomes, one can visualize the longitudinal biodistribution of the TAA and evaluate whether the TAA slowly clears from the depot site, resulting in a potentiated immune response. To evaluate the longitudinal clearance of the DepoVaxTM vaccine components, mice underwent a C3 (HPV16 model) challenge using SPIO conjugated to the TAA or associated with the lipid.